Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Abstract The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-022-00329-w |